Intralesional PV-10 Chemoablation of Metastatic Melanoma

Melanoma Clinical Trial

Official title:

A Phase 1 Safety and Tolerability Study of Intralesional PV-10 Chemoablation in Subjects With Metastatic Melanoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00219843
• Other study ID #: PV-10-MM-01
• Status: Completed
• Phase: Phase 1
• First received: September 14, 2005
• Last updated: August 22, 2007
• Start date: August 2005
• Est. completion date: August 2007

Study information

• Verified date: August 2007
• Source: Provectus Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationAustralia: Department of Health and Ageing Therapeutic Goods Administration
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of metastatic melanoma. This study will also include a preliminary assessment of response of treated and untreated lesions by clinical evaluation at follow-up of 12 to 24 weeks following IL PV-10 treatment.

Description:

This is a two center, open label, ascending dose study. Subjects with at least two measurable melanoma lesions will receive a single intralesional injection of 10% PV-10 solution into each of one to twenty (20) target lesions. Additionally, one to three measurable untreated non-target lesions will be followed for assessment of bystander response. Systemic and locoregional adverse events will be monitored over the study interval. Dose escalation will be made only if no subjects at the first dose level have a Grade 3 non-hematological or Grade 4 hematological toxicity over a period of two weeks after PV-10 administration. Subject accrual and PV-10 administration at the second dose level will be stopped if more than 1 subject has a treatment related Grade 3 non-hematological or Grade 4 hematological toxicity within a period of two weeks after PV-10 administration.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: August 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed metastatic melanoma, American Joint Committee on Cancer (AJCC) Stage III (regional lymph node metastasis, in-transit metastasis or satellite metastasis) or Stage IV (distant metastasis)

• Measurable disease in at least two lesions, each lesion = 6 cm in diameter

• Performance status: ECOG 0-2

• Life expectancy: at least 6 months

• Hematopoietic:

• White blood cell count (WBC) at least 3000/mm3

• Absolute neutrophil count (ANC) at least 1.5 (1,500/mm3)

• Platelet count at least 100,000/mm3

• Renal function:

• Creatinine = 2.0 mg/dL

• Hepatic function:

• Bilirubin = 2.0 mg/dL

• AST/ALT = 3 times the upper limit of normal (ULN)

• Cardiovascular function:

• No major cardiovascular disease

• Thyroid function:

• T3 (serum triiodothyronine), T4 (serum thyroxine) and THS (serum thyrotropin) within normal limits

• Immunological function:

• Adequate immune system function in the opinion of the investigator

Exclusion Criteria:

• Radiation therapy within 4 weeks or to any study lesion within 12 weeks

• Chemotherapy or other systemic cancer therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin) or regional chemotherapy (limb infusion or perfusion) within 12 weeks

• Local treatment (e.g., surgery, cryotherapy, radiofrequency ablation) to the treatment area within 4 weeks

• Investigational agents within 4 weeks (or 5 half-lives)

• Anti-tumor vaccine therapy within 12 weeks

• Concurrent illness:

• Severe diabetes or extremity complications due to diabetes

• Significant concurrent disease or illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the investigator, compromise subject safety or compliance or interfere with interpretation of study results

• Thyroid autoregulatory dysfunction, including thyroid disease (subclinical or ongoing), goiter, partial thyroidectomy, prior radioiodine- or surgically-treated Graves' hyperthyroidism, or cystic fibrosis

• Pregnancy or fertile female subjects who are not using effective contraception

• Concurrent medications:

• Subjects taking medications with a significant risk of photosensitization, such as thiazides, within one week (or 5 half-lives) of study treatment.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• PV-10 (rose bengal disodium, 10%)

Locations

Country	Name	City	State
Australia	Sydney Melanoma Unit	North Sydney	New South Wales
Australia	Newcastle Melanoma Unit	Waratah	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Provectus Pharmaceuticals

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: adverse experience
Secondary	Efficacy: objective response rate of target lesions and untreated non-target lesions